MedTrace Logo

Screening for Cardiac Amyloidosis With Nuclear Imaging for Minority Populations

NCT03812172 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 646

Last updated 2025-11-19

Study results available
· View outcomes & findings →

Summary

In this study, the investigators recruited a cohort of elderly Black and Hispanic patients with heart failure to define the number of patients who have cardiac amyloidosis by utilizing highly sensitive heart imaging and blood tests. The investigators also explored differences in genetics and sex as they relate to heart failure disease progression in cardiac amyloidosis.

Conditions

  • Amyloid Cardiomyopathy, Transthyretin-Related

Interventions

DRUG

99mTc-PYP or 99m Tc-HDP

10-25 mCi of 99mTc-PYP (or 99m Tc-HDP) was administered intravenously and imaging was performed after 3 hours.

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Boston Medical Center

    collaborator OTHER

  • Harlem Hospital Center

    collaborator OTHER

  • The Scripps Research Institute

    collaborator OTHER

  • Yale University

    collaborator OTHER

  • Mathew S. Maurer, MD

    lead OTHER

Principal Investigators

  • Mathew S. Maurer, MD · Columbia University

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-15
Primary Completion
2024-06-12
Completion
2024-12-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03812172 on ClinicalTrials.gov